论文部分内容阅读
2001年12月10日,瑞士罗氏(Roche)公司宣布将出资16亿美元收购日本中外(Chugai)制药公司的多数股票,这也使得罗氏再次跻身世界前10位制药公司的行列,并且为公司在第2大药品销售市场日本的未来发展奠定了坚实的基础。这是首度非日本公司控股日本的大制药企业,但如同罗氏对待基因技术(Genentech)公司的策略一样,中外将保留自己的经营理念和企业发展文化。 为了确保合并方案不受反托拉斯法影响,在两家公司合并前中外将剥离其美国的子公司Gen-Probe,该公司同罗氏的诊断业务存在竞争。之后,罗氏将购买中外制药50.1％的股票,并将同罗氏的日本子公司Nippon Roche合并。新公司的目标是在3年内实现
On December 10, 2001, Roche announced that it will spend 1.6 billion U.S. dollars to acquire the majority of Chugai’s pharmaceutical companies, making Roche one of the top 10 pharmaceutical companies in the world once again, The second largest drug sales market in Japan’s future development has laid a solid foundation. This is the first time a non-Japanese company holds Japan’s big pharmaceutical company, but like Roche’s strategy for Genentech, both China and foreign countries will retain their business philosophy and corporate culture of development. To ensure the merger is not affected by the antitrust laws, both China and foreign companies will strip their U.S. subsidiary, Gen-Probe, before the two companies merge, rivaling Roche’s diagnostic business. Roche will then buy 50.1% of Chugai’s shares and will merge with Roche’s Japanese subsidiary, Nippon Roche. The new company’s goal is to be achieved in three years